Publicaciones (57) Publicaciones de Marisol Aymerich Soler

2024

  1. Nigrostriatal degeneration determines dynamics of glial inflammatory and phagocytic activity

    Journal of Neuroinflammation, Vol. 21, Núm. 1

2023

  1. Microglia and astrocyte activation is region-dependent in the α-synuclein mouse model of Parkinson's disease

    GLIA, Vol. 71, Núm. 3, pp. 571-587

  2. Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models

    Neurobiology of Disease, Vol. 183

2021

  1. Expression of endothelial nox5 alters the integrity of the blood-brain barrier and causes loss of memory in aging mice

    Antioxidants, Vol. 10, Núm. 8

  2. Gut microbial dysbiosis after traumatic brain injury modulates the immune response and impairs neurogenesis

    Acta Neuropathologica Communications, Vol. 9, Núm. 1

  3. Understanding the potential role of sirtuin 2 on aging: Consequences of sirt2.3 overexpression in senescence

    International Journal of Molecular Sciences, Vol. 22, Núm. 6, pp. 1-23

2020

  1. Cannabinoid receptor type 2 as a therapeutic target for Parkinson’s disease

    Diagnosis and Management in Parkinson’s Disease: The Neuroscience of Parkinson’s Disease, Volume 1 (Elsevier), pp. 557-573

  2. Cb2 receptors and neuron–glia interactions modulate neurotoxicity generated by magl inhibition

    Biomolecules, Vol. 10, Núm. 8, pp. 1-15

2019

  1. Dopamine receptor D3 expression is altered in CD4+ T-cells from Parkinson's disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model

    Frontiers in Immunology, Vol. 10, Núm. MAY

  2. Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions

    Journal of Neuroinflammation, Vol. 16, Núm. 1

2018

  1. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

    Biochemical Pharmacology, Vol. 157, pp. 67-84

  2. Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples

    Neurotherapeutics, Vol. 15, Núm. 3, pp. 742-750

  3. Stereological estimates of glutamatergic, GABAergic, and cholinergic neurons in the pedunculopontine and laterodorsal tegmental nuclei in the rat

    Frontiers in Neuroanatomy, Vol. 12

  4. The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia

    Neurobiology of Disease, Vol. 118, pp. 64-75

2017

  1. GPR55: A therapeutic target for Parkinson's disease?

    Neuropharmacology, Vol. 125, pp. 319-332

  2. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease

    Neuropharmacology, Vol. 113, pp. 110-123

  3. Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks

    Neuroscience and Biobehavioral Reviews, Vol. 76, pp. 380-395

2016

  1. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease

    Brain, Behavior, and Immunity, Vol. 57, pp. 94-105

  2. Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors

    Molecular Neurobiology, Vol. 53, Núm. 4, pp. 2312-2319

2015

  1. Structures for G-Protein-Coupled Receptor Tetramers in Complex with G Proteins

    Trends in Biochemical Sciences